Related references
Note: Only part of the references are listed.Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Cristina Masini et al.
EUROPEAN UROLOGY (2022)
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial
Shankar Siva et al.
EUROPEAN UROLOGY (2022)
A Story of Hypofractionation and the Table on the Wall
Robert Timmerman
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
Raquibul Hannan et al.
EUROPEAN UROLOGY ONCOLOGY (2022)
Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review
Gianluca Ingrosso et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report
Charles Marchand Crety et al.
CASE REPORTS IN ONCOLOGY (2021)
Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
Liru He et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma
Ciro Franzese et al.
JOURNAL OF UROLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
Time to abandon single-site irradiation for inducing abscopal effects
Eric D. Brooks et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Rohann J. M. Correa et al.
EUROPEAN UROLOGY FOCUS (2019)
Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies
Nicholas G. Zaorsky et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group
Emmanuel Meyer et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014
M. Stenman et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study
Yun Bai et al.
ONCOTARGETS AND THERAPY (2018)
Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature
G. Francolini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen et al.
NATURE (2016)
Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma
Mark C. Ranck et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
TUMOR CONTROL OUTCOMES AFTER HYPOFRACTIONATED AND SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES FROM RENAL CELL CARCINOMA
Michael J. Zelefsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
QUANTITATIVE ANALYSES OF NORMAL TISSUE EFFECTS IN THE CLINIC (QUANTEC): AN INTRODUCTION TO THE SCIENTIFIC ISSUES
Soren M. Bentzen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H. Benedict et al.
MEDICAL PHYSICS (2010)
Renal radiosurgery: Initial clinical experience with histological evaluation
Lee E. Ponsky et al.
SURGICAL INNOVATION (2007)
Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy
JS Lam et al.
JOURNAL OF UROLOGY (2005)